Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

CLEOPATRA Final Results: Perjeta Extends Life Significantly

Final results from the CLEOPATRA trial were presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid at the end of September. They were also later published in the New England Journal of Medicine, in February 2015. The results show the combination of trastuzumab and pertuzumab, along with chemotherapy, lengthened the lives of women with HER2-positive metastatic breast cancer by a median 15.7 months. The increase is being called unprecedented.

Radiation Therapy After Breast Implant Reconstruction Associated With Lower Levels of Well-Being

According to research, women who have breast implant reconstruction, followed by radiation therapy, are not as happy with the results and report lower levels of well-being than women who have the same reconstruction without radiation therapy.

Double Mastectomy Shows Same Benefit As Lumpectomy for Average Risk

A recent study of California women with early-stage breast cancer showed that bilateral mastectomy has the same impact on survival as breast-conserving surgery, or lumpectomy, followed by radiation therapy.

ASCO Updates Guideline on Length of Tamoxifen Treatment

After evaluating long-term results from recent studies, the American Society of Clinical Oncology, ASCO, issued a guideline update for tamoxifen therapy for hormone receptor-positive breast cancer.

The update advises doctors to offer up to 10 years of tamoxifen treatment, instead of the previous standard 5-year duration

ASCO Breast Study Focuses on Preserving Fertility in Young Women

Young Women's Initiative Icon

LBBC highlights results of a phase III clinical trial studying a medicine used to protect premenopausal women’s ovaries during chemotherapy. Findings were announced during the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.

Carboplatin Helpful in Treating Triple-Negative Breast Cancer Before Surgery

Researchers with the phase II GeparSixto trial found that women with triple-negative breast cancer were significantly more likely to achieve pathological complete response, or pCR, when carboplatin was added to their course of other anti-cancer medicines. For this study, pCR was defined as the absence of cancer after treatment given before surgery.

Q&A: Dr. Jennifer Klemp Answers Questions About PALB2 Research

A recent study published in The New England Journal of Medicine looked at harmful mutations, or changes in the DNA of a cell, found on the PALB2 gene. The study found that, like BRCA1 and BRCA2 gene mutations, PALB2 mutations greatly increase a person’s chance of getting breast cancer.

ASCO Breast Reports on Recurrence after Early Chemotherapy

LBBC highlights a study reported on the first day of the American Society of Clinical Oncology 2014 Breast Cancer Symposium: an analysis of breast cancer recurrence rates after pre-surgery, or neoadjuvant, chemotherapy.

Researchers Identify Barriers to Early-Stage Breast Cancer Treatment

Although more women are having lumpectomies, an evaluation of data in the National Cancer Database found socioeconomic barriers prevent some from choosing this surgery. Meeghan Ann Lautner, MD, of the University of Texas San Antonio, announced findings at the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.

Everolimus May Help Those With HER2-positive Breast Cancer That No Longer Responds Well to Trastuzumab

Adding everolimus could make trastuzumab work better in women who aren’t seeing the same benefits this medicine once gave them. But everolimus isn’t without risk – it has the potential to lower the user’s quality of life.